A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironmentsKevin C. Barry, Matthew F. Krummel, Adil Daud et al.|Nature Medicine|2018Cited by 1k
Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell ImmunityMikhail Binnewies, Matthew F. Krummel, Adriana M. Mujal et al.|Cell|2019Cited by 617
Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodesMaha K. Rahim, Matthew H. Spitzer, Trine Line Hauge Okholm et al.|Cell|2023Cited by 410
Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19Monique G.P. van der Wijst, Chun Ye, Sara E. Vazquez et al.|Science Translational Medicine|2021Cited by 237
Discovering dominant tumor immune archetypes in a pan-cancer censusAlexis J. Combes, Sima P. Porten, Bushra Samad et al.|Cell|2021Cited by 172